<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta name="description" content="Learn how CDKL5 AAV9 gene therapy restores protein expression, meet the team, and explore the data guiding our path to first-in-human trials.">
    <title>About Us | CDKL5 Gene Therapy Coalition</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="css/style.css">
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-XXXXXXX-X"></script>
    <script>
        window.dataLayer = window.dataLayer || [];
        function gtag(){dataLayer.push(arguments);} // minimal GA placeholder
        gtag('js', new Date());
        gtag('config', 'UA-XXXXXXX-X');
    </script>
</head>
    <div data-include="inc/header.html"></div>

    <main>
        <div class="container">
            <section class="section fade-in">
                <span class="badge">Root-cause therapy</span>
                <h1>About our CDKL5 AAV9 program</h1>
                <p>We are a coalition of families, clinicians, and drug developers partnering to deliver a one-time gene therapy that addresses the fundamental deficit driving CDKL5 Deficiency Disorder (CDD). By transporting a functional CDKL5 gene directly into neurons, we aim to restore protein expression, stabilize circuitry, and reclaim developmental potential.</p>
            </section>

            <section class="section fade-in" aria-labelledby="mechanism-heading">
                <h2 id="mechanism-heading">How the therapy works</h2>
                <div class="card-grid">
                    <article class="card">
                        <h3>Targeted delivery</h3>
                        <p>The AAV9 capsid has a proven affinity for central nervous system cells. Delivered intracerebroventricularly (i.c.v.), it disperses through cerebrospinal fluid to reach cortex, hippocampus, and deep brain nuclei.[1][5]</p>
                    </article>
                    <article class="card">
                        <h3>Restoring CDKL5 protein</h3>
                        <p>Once in the nucleus, the payload expresses full-length CDKL5 protein to compensate for the endogenous gene disruption. This supports synaptic scaling, dendritic arborization, and seizure suppression.[1][5]</p>
                    </article>
                    <article class="card">
                        <h3>Sustainable expression</h3>
                        <p>Long-term preclinical data indicate durable expression with no integration into genomic DNA, aligning with established AAV safety expectations from approved therapies like Zolgensma® and Luxturna®.[2]</p>
                    </article>
                </div>
            </section>

            <section class="section fade-in" aria-labelledby="team-heading">
                <h2 id="team-heading">Leadership team</h2>
                <div class="card-grid">
                    <article class="card">
                        <h3>Dr. Gai Ayalon, Ph.D.</h3>
                        <p><strong>Drug Development Advisor</strong></p>
                        <p>Neuroscientist leading Child's Cure Genetic Research gene therapy program through clinical development. Previously led clinical development programs for pediatric neurodevelopmental disorders at Ultragenyx Pharmaceutical.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Nalin Gupta</h3>
                        <p><strong>Clinical Advisor</strong></p>
                        <p>Pediatric neurologist specializing in rare genetic disorders with expertise in clinical trial design and regulatory pathways.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Adam Numis</h3>
                        <p><strong>Clinical Investigator</strong></p>
                        <p>Pediatric neurologist with focus on epilepsy and developmental disorders, contributing to natural history studies and trial protocols.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Heather Olson</h3>
                        <p><strong>Clinical Investigator</strong></p>
                        <p>Pediatric epileptologist at Boston Children's Hospital with extensive experience in CDKL5 Disorder clinical management and research.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Jacinthe Gingras</h3>
                        <p><strong>Preclinical Research Advisor</strong></p>
                        <p>Molecular biologist specializing in gene therapy vector development and CNS delivery mechanisms.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Lauren Black</h3>
                        <p><strong>Clinical Research Coordinator</strong></p>
                        <p>Expert in clinical trial operations and patient advocacy for rare disease populations.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Michael Templin</h3>
                        <p><strong>Scientific Advisor</strong></p>
                        <p>Neuroscientist with expertise in neurological disease models and therapeutic validation.</p>
                    </article>
                    <article class="card">
                        <h3>Tracy Johnson</h3>
                        <p><strong>Program Manager</strong></p>
                        <p>Experienced program manager coordinating cross-functional teams and regulatory submissions for gene therapy programs.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Sangeeta Joshi</h3>
                        <p><strong>Regulatory Affairs Advisor</strong></p>
                        <p>Regulatory strategist guiding IND preparation and FDA interactions for pediatric rare diseases.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Tim Cote</h3>
                        <p><strong>Clinical Development Advisor</strong></p>
                        <p>Clinical development expert with deep experience in orphan drug programs and accelerated pathways.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Paul Herzich</h3>
                        <p><strong>Medical Monitor</strong></p>
                        <p>Pediatric specialist providing medical oversight and safety monitoring for clinical trials.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Kruti Patel</h3>
                        <p><strong>Clinical Operations Lead</strong></p>
                        <p>Clinical operations specialist managing site selection, patient recruitment, and trial logistics.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Lester Suarez</h3>
                        <p><strong>Biostatistics Advisor</strong></p>
                        <p>Biostatistician designing adaptive trial protocols and endpoint analysis for rare disease studies.</p>
                    </article>
                    <article class="card">
                        <h3>Ilya Musavey</h3>
                        <p><strong>Technical Operations</strong></p>
                        <p>Operations specialist managing GMP manufacturing partnerships and supply chain logistics.</p>
                    </article>
                    <article class="card">
                        <h3>Sarah Caffey</h3>
                        <p><strong>CMC Manufacturing Team Member</strong></p>
                        <p>Supports manufacturing operations and GMP production coordination for CMC activities, liaising with manufacturing partners to ensure quality and supply readiness.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Matthew Simon</h3>
                        <p><strong>Translational Medicine Advisor</strong></p>
                        <p>Physician-scientist bridging preclinical research and clinical application for neurological gene therapies.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Vincent Pons</h3>
                        <p><strong>Scientific Advisor</strong></p>
                        <p>Molecular biologist with expertise in AAV vector design and neurodevelopmental disorder mechanisms.</p>
                    </article>
                    <article class="card">
                        <h3>Dr. Kristin Loomis</h3>
                        <p><strong>Preclinical Development Lead</strong></p>
                        <p>Leading toxicology studies and IND-enabling pharmacology for AAV9-CDKL5 gene therapy vector.</p>
                    </article>
                </div>
            </section>

            <section class="section fade-in" aria-labelledby="data-heading">
                <h2 id="data-heading">Preclinical evidence at a glance</h2>
                <div class="card-grid">
                    <article class="card">
                        <h3>Neuron targeting</h3>
                        <ul class="info-list">
                            <li>i.c.v. dosing transduced ≥50% of neurons in cortex, hippocampus, and thalamus.[1]</li>
                            <li>Improved hindlimb clasping, open-field exploration, and contextual fear conditioning.[5]</li>
                        </ul>
                    </article>
                    <article class="card">
                        <h3>Functional recovery</h3>
                        <ul class="info-list">
                            <li>UX055 restored motor and cognitive function in CDKL5 knockout mouse models.[2]</li>
                            <li>Human induced pluripotent stem cell organoids showed corrected hyperexcitability.[2]</li>
                        </ul>
                    </article>
                    <article class="card">
                        <h3>Safety and biodistribution</h3>
                        <ul class="info-list">
                            <li>Favorable biodistribution compared with intrathecal delivery, reducing peripheral exposure.[5]</li>
                            <li>No vector-related toxicity observed at efficacious doses (3e11–5e11 vg/g brain).[1]</li>
                        </ul>
                    </article>
                </div>
            </section>

            <section class="section fade-in" aria-labelledby="milestones-heading">
                <h2 id="milestones-heading">Milestones</h2>
                <ul class="info-list">
                    <li>April 2024: Completed vector design freeze and pre-IND meeting feedback integration.</li>
                    <li>Q4 2024: Launch translational toxicology in partnership with CRO network.</li>
                    <li>Q2 2025: Manufacture GMP batch and finalize release assays.</li>
                    <li>Q2 2026: Target first participant dosing pending $3.5M fundraising goal.</li>
                </ul>
            </section>
        </div>
    </main>

    <div data-include="inc/footer.html"></div>

    <script src="js/includes-loader.js" defer></script>
    <script src="js/script.js" defer></script>
</body>
</html>
